Stock CRNX CRINETICS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
47.47 USD -2.39% Intraday chart for Crinetics Pharmaceuticals, Inc. -7.65% +33.42%
May. 23 Morgan Stanley Raises Price Target on Crinetics Pharmaceuticals to $70 From $50, Maintains Overweight Rating MT
May. 22 Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts CI

Evolution of the average Target Price on Crinetics Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f31c5bc07818e3.TUF4LcokagUmVXOYGa4e6XnE_2sGrQICZQALMA524hA.dQYPaJ1oOVJDF0TtVdRWrSyvvVtixXNmKnJ5WWUQkEYAM0luq3clalQ9FA~31be217b959214e183dcbf351dec6ad0

Analyst Recommendations on Crinetics Pharmaceuticals, Inc.

Morgan Stanley Raises Price Target on Crinetics Pharmaceuticals to $70 From $50, Maintains Overweight Rating MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing MT
Piper Sandler Adjusts Price Target on Crinetics Pharmaceuticals to $97 From $56, Maintains Overweight Rating MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $664,763, According to a Recent SEC Filing MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $2,648,150, According to a Recent SEC Filing MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $449,793, According to a Recent SEC Filing MT
JMP Securities Adjusts Price Target on Crinetics Pharmaceuticals to $80 From $60, Maintains Market Outperform Rating MT
Oppenheimer Raises Crinetics Pharmaceuticals Price Target to $55 From $54, Maintains Outperform Rating MT
JonesTrading Raises Crinetics Pharmaceuticals' Price Target to $56 From $52, Maintains Buy Rating MT
HC Wainwright Raises Crinetics Pharmaceuticals Price Target to $60 From $50, Maintains Buy Rating MT
Oppenheimer Adjusts Crinetics Pharmaceuticals Price Target to $54 From $48, Maintains Outperform Rating MT
HC Wainwright Adjusts Crinetics Pharmaceuticals Price Target to $50 From $42, Maintains Buy Rating MT
Citigroup Initiates Crinetics Pharmaceuticals With Buy Rating, $68 Price Target MT
Cantor Fitzgerald Adjusts Price Target on Crinetics Pharmaceuticals to $65 From $50, Maintains Overweight Rating MT
Oppenheimer Raises Crinetics Pharmaceuticals Price Target to $48 From $46, Maintains Outperform Rating MT
Baird Adjusts Crinetics Pharmaceuticals Price Target to $52 From $45, Maintains Outperform Rating MT
Investors got more clues that rate cuts are imminent Our Logo
Evercore ISI Adjusts Price Target on Crinetics Pharmaceuticals to $48 From $41, Maintains Outperform Rating MT
Oppenheimer Adjusts Crinetics Pharmaceuticals Price Target to $46 From $40, Maintains Outperform Rating MT
Baird Adjusts Crinetics Pharmaceuticals Price Target to $45 From $43, Maintains Outperform Rating MT
Oppenheimer Initiates Coverage on Crinetics Pharmaceuticals With Outperform Rating, $40 Price Target MT
HC Wainwright Trims Price Target on Crinetics Pharmaceuticals to $33 From $35, Maintains Buy Rating MT
JMP Securities Adjusts Crinetics Pharmaceuticals Price Target to $43 From $41, Maintains Market Outperform Rating MT
Piper Sandler Initiates Coverage on Crinetics Pharmaceuticals With Overweight Rating, $56 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
47.47 USD
Average target price
65.07 USD
Spread / Average Target
+37.08%
High Price Target
97 USD
Spread / Highest target
+104.34%
Low Price Target
47 USD
Spread / Lowest Target
-0.99%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Crinetics Pharmaceuticals, Inc.

Morgan Stanley
Piper Sandler
HC Wainwright
JonesTrading Institutional Services
Oppenheimer
JMP Securities
Citigroup
Cantor Fitzgerald
Baird
Evercore ISI
LifeSci Capital
SVB Securities LLC
JPMorgan Chase

Ratings for Crinetics Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CRNX Stock
  4. Consensus Crinetics Pharmaceuticals, Inc.